Under the agreement, GlaxoSmithKline has paid Genstruct an upfront fee pursuant to an agreement signed in 2005 and will continue to fund research projects for the term of the agreement. Additional financial terms of the deal have not been disclosed.
Genstruct will continue to collaborate with GSK’s oncology therapeutic area to identify molecular mechanisms of action for several drug candidates. Thus far, Genstruct has built causal models for various cancer states and interrogated the models using computer-aided causal reasoning to define mechanistic biomarkers.
The companies have confirmed that similar work will continue in the new phase of the collaboration.
“The first phase of our collaboration has already proved fruitful for Genstruct and GSK through the identification of drug mechanisms as an aid to clinical development,” said Dr Keith Elliston, president and CEO of Genstruct. “We are excited to address the scientific challenges that lay before us.”